A landmark population-based cohort study by Kim et al. provides definitive evidence that adherence to follow-up examination after a positive fecal occult blood test (FOBT) is directly linked to reduced colorectal cancer (CRC) mortality. Analyzing data from over 258,000 individuals in Korea with positive FOBT results, the study rigorously evaluates the impact of compliance with colonoscopy or double-contrast barium enema (DCBE) on long-term outcomes. The findings are unequivocal: non-compliance significantly increases the risk of dying from CRC.
The researchers divided patients into two groups: those who completed follow-up within one year (142,269 individuals) and those who did not (116,550).83-79-4 custom synthesis Notably, the proportion of non-compliant patients—approximately 45%—is alarmingly high but consistent with previous reports from other national screening programs. This highlights a systemic challenge in healthcare delivery, where initial test positivity does not automatically translate into diagnostic action. The compliant group showed a higher rate of CRC detection (4.2%) compared to the non-compliant group (2.441798-33-0 Description 6%), suggesting that earlier diagnosis may be achieved through timely follow-up, possibly including indolent cancers that would otherwise progress.
After adjusting for multiple confounding factors such as age, sex, comorbidities, and socioeconomic status, multivariate analysis revealed that non-compliance was independently associated with a 70% increased risk of CRC-specific death, with a hazard ratio of 1.70 (95% CI: 1.52–1.90). This robust association underscores that the survival benefit of screening is not inherent to the FOBT alone but is contingent upon subsequent colonoscopic evaluation.PMID:25905189 Without this step, the potential for early intervention and cancer prevention is lost.
While the study does not distinguish between the effectiveness of colonoscopy versus DCBE due to the combined compliant group, it confirms that both modalities contribute to improved outcomes when used appropriately. In the original cohort, only 27.6% opted for colonoscopy, with the remainder choosing DCBE—an important consideration given that colonoscopy offers superior lesion detection and the ability to perform immediate polypectomy. Nevertheless, even delayed follow-up within one year was still associated with better survival, indicating that the window for meaningful intervention remains open beyond the ideal timeframe.
The authors acknowledge limitations, including the inability to determine how non-compliant patients were diagnosed with CRC. It is highly probable that many presented with symptoms—such as bleeding, weight loss, or obstruction—leading to diagnosis outside the screening context. These individuals likely represent cases of interval cancer or missed opportunity, further emphasizing the risks of poor follow-up.
This study reinforces the necessity of integrating patient navigation, automated reminders, and performance monitoring into national screening programs. Ensuring that every positive FOBT leads to timely diagnostic evaluation is no longer optional—it is a clinical imperative. With strong population-level evidence now confirming that follow-up reduces CRC mortality, health systems must act decisively to eliminate gaps in care. Only then can colorectal cancer screening fully realize its life-saving potential.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com
